Benitec Biopharma Profit Margin 2014-2022 | BNTC

Current and historical gross margin, operating margin and net profit margin for Benitec Biopharma (BNTC) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Benitec Biopharma net profit margin as of September 30, 2022 is 0%.
Benitec Biopharma Annual Profit Margins
Benitec Biopharma Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.005B $0.000B
Benitec Biopharma Limited is a biotechnology company which developed a patented gene silencing technology delivered by gene therapy called DNA directed RNA interference. The company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including hepatitis C and B, drug resistant lung cancer and wet age-related macular degeneration. Benitec Biopharma Limited is based in Sydney, Australia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $172.495B 10.52
GSK (GSK) United Kingdom $71.890B 9.01
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.433B 19.52
Ginkgo Bioworks Holdings (DNA) United States $3.861B 0.00
Myovant Sciences (MYOV) United Kingdom $2.605B 0.00
Arcus Biosciences (RCUS) United States $2.586B 38.81
Biohaven (BHVN) United States $1.141B 0.00
Emergent Biosolutions (EBS) United States $0.599B 4.71
Zymeworks (ZYME) Canada $0.478B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.278B 0.00
Enzo Biochem (ENZ) United States $0.096B 0.00
SQZ Biotechnologies (SQZ) United States $0.046B 0.00
Gelesis Holdings (GLS) United States $0.035B 0.00
Ambrx Biopharma (AMAM) United States $0.019B 0.00